# A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemor

Source: https://onco.cc/trials/nct07010263/  
OnCo record `nct07010263` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Ivonescimab in small-cell lung cancer, run by Akeso, now recruiting.

## Summary

A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy is a phase 3 interventional study registered as NCT07010263 by Akeso, with 560 participants planned, started 2025-06-13 and due to reach its primary completion in 2028-12-31. Interventions recorded: AK112, Placebo. Conditions listed: Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07010263
- Phase: 3
- Setting: A Multicenter, Randomized, Double-blind, Phase III Clinical Study of Comparing the Efficacy and Safety of AK112 (PD-1/VEGF Bispecific Antibody) Versus Placebo as Consolidation Treatment for Patients With Limited Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
- Sponsor: Akeso
- Enrolled: 560

## Sources

- ClinicalTrials.gov NCT07010263: https://clinicaltrials.gov/study/NCT07010263

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Ivonescimab](https://onco.cc/drugs/ivonescimab/)
- companies: [Akeso](https://onco.cc/companies/akeso/)

---
JSON: https://onco.cc/api/v1/entities/nct07010263.json